Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier

被引:45
|
作者
Luker, GD
Rao, VV
Crankshaw, CL
Dahlheimer, J
PiwnicaWorms, D
机构
[1] WASHINGTON UNIV,SCH MED,DEPT RADIOL,LAB MOL RADIOPHARMACOL,ST LOUIS,MO 63110
[2] WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110
关键词
D O I
10.1021/bi971931z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The multidrug resistance (MDR1) P-glycoprotein functions as a broad specificity efflux transporter of structurally diverse natural product and xenobiotic compounds. P-glycoprotein also is an important component of the functional blood-brain barrier. To enable further studies of function and modulation of MDR1 P-glycoprotein in vitro and in vivo, two novel phosphine technetium(III) complexes were designed and characterized: trans-[2,2'-(1,2-ethanediyldiimino)bis(1,5-methoxy-5-methyl-4-oxohexenyl)]bis[methylbis(3-methoxy-1-propyl)phosphine]Tc(III) (Tc-Q58) and trans-[5,5'-(1,2-ethanediyl diimino)bis(2-ethoxy-2-methyl-3-oxo-4-pentenyl)]bis[dimethyl(3-methoxy-1-propyl)phosphine)]Tc(III) (Tc-Q63). In human drug-sensitive KB 3-1 cells and multidrug-resistant KB 8-5 and 8-5-11 derivative cell lines, expressing nonimmunodetectable, low, and high levels of MDR1 P-glycoprotein, respectively, accumulation of Tc-Q58 and Tc-Q63 was inverse to expression of the transporter. Differences between drug-sensitive and multidrug-resistant cells, while detectable at picomolar concentrations of each radiopharmaceutical, were independent of tracer concentration, Ratios of tracer accumulation in KB 3-1 and 8-5 cells were 62.3 and 48.1 for Tc-Q58 and Tc-Q63, respectively. Cell contents of Tc-Q58 and Tc-Q63 were enhanced up to 60-fold in MDR cells by known modulators of MDR1 P-glycoprotein, while drugs not in the multidrug-resistant phenotype had no effect on their accumulation. In KB 8-5 cells, potency of modulators was GF120918 much greater than cyclosporin A > verapamil. Accumulation of Tc-Q58 and Tc-Q63 in Sf9 insect cells infected with a recombinant baculovirus containing human MDR1 P-glycoprotein was reduced in a GF120918-reversible manner (EC50 less than or equal to 70 nM) compared with cells infected with a wild-type baculovirus. By contrast, cell contents of Tc-Q58 or Tc-Q63 in Sf9 cells expressing the homologous MDR3 P-glycoprotein did not differ from wild-type virus, Demonstrating molecular targeting of these complexes in vivo, distribution and retention of Tc-Q58 in brain tissue of FVB mice treated with a saturating dose of GF120918 and mice deficient in the mdr1a gene [mdr1a (-/-)] were enhanced 180% and 520% over control, respectively. Exploiting the gamma-emission spectrum of Tc-99m, increased uptake of Tc-Q58 in brain tissue of mdr1a (-/-) mice was readily detected noninvasively by scintigraphic imaging. Thus, both Tc-Q58 and Tc-Q63 are demonstrated to be substrates for transport by MDR1 P-glycoprotein, broadening the specificity of this transporter to include phosphine-containing metal complexes. As shown with Tc-Q58, these Q complexes can be used to detect transport activity and modulation of MDR1 P-glycoprotein in vitro and to directly monitor the functional status of P-glycoprotein at the blood-brain barrier in vivo.
引用
收藏
页码:14218 / 14227
页数:10
相关论文
共 50 条
  • [31] Impact of P-glycoprotein on the efficiency of carbamazepine transport across the blood-brain barrier
    Zybina, A.
    Kulichenkova, K.
    Abbasova, K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S197 - S197
  • [32] Oseltamivir (Tamiflu™) efflux transport at the blood-brain barrier via P-glycoprotein
    Morimoto, Kaori
    Nakakariya, Masanori
    Kanauchi, Itaru
    Shirasaka, Yoshiyuki
    Tamai, Ikumi
    Ogihara, Takuo
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2007, 127 : 111 - 112
  • [33] Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein
    Crankshaw, CL
    Marmion, M
    Luker, GD
    Rao, V
    Dahlheimer, J
    Burleigh, BD
    Webb, E
    Deutsch, KF
    Piwnica-Worms, D
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (01) : 77 - 86
  • [34] Pharmacokinetics of P-Glycoprotein Inhibition in the Rat Blood-Brain Barrier
    Syvanen, Stina
    Hooker, Andrew
    Rahman, Obaidur
    Wilking, Helena
    Blomquist, Gunnar
    Langstrom, Bengt
    Bergstrom, Mats
    Hammarlund-Udenaes, Margareta
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (12) : 5386 - 5400
  • [35] P-glycoprotein in the blood-brain barrier versus sensitivity to ivermectin
    Skipor, J
    Thiery, JC
    MEDYCYNA WETERYNARYJNA-VETERINARY MEDICINE-SCIENCE AND PRACTICE, 2005, 61 (04): : 384 - 386
  • [36] Corticosteroid Regulation of P-Glycoprotein in the Developing Blood-Brain Barrier
    Iqbal, Majid
    Gibb, William
    Matthews, Stephen G.
    ENDOCRINOLOGY, 2011, 152 (03) : 1067 - 1079
  • [37] Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
    Bartels, A. L.
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (26) : 2771 - 2777
  • [38] P-glycoprotein function in the blood-brain barrier of epileptic rats
    Syvanen, S.
    Luurtsema, G.
    Molthoff, C. F. M.
    Windhorst, A. D.
    Huisman, M. C.
    Lammertsma, A. A.
    Voskuyl, R. A.
    de lange, E. C. M.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2009, 29 : S209 - S209
  • [39] Decreased blood-brain barrier P-glycoprotein function with aging
    Bauer, Martin
    Karch, Rudolf
    Neumann, Friederike
    Abrahim, Aiman
    Kletter, Kurt
    Mueller, Markus
    Langer, Oliver
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [40] Involvement of P-glycoprotein in an in vitro blood-brain barrier model
    Joly, B
    Lecureur, V
    Puozzo, C
    Guillouzo, A
    Fardel, O
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 9 (05) : 1029 - 1033